287 related articles for article (PubMed ID: 34453703)
1. The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic.
Tran A; Witek TJ
Pharmaceut Med; 2021 Jul; 35(4):203-213. PubMed ID: 34453703
[TBL] [Abstract][Full Text] [Related]
2. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
Rizk JG; Forthal DN; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Pfeiffer JP; Lewin JC
Drug Discov Today; 2021 Feb; 26(2):593-603. PubMed ID: 33253920
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords.
Bhimraj A; Morgan RL; Shumaker AH; Lavergne V; Baden L; Cheng VC; Edwards KM; Gandhi RT; Gallagher JC; Muller WJ; O'Horo JC; Shoham S; Wollins DS; Falck-Ytter Y
Clin Infect Dis; 2022 May; 74(9):1686-1690. PubMed ID: 34668010
[TBL] [Abstract][Full Text] [Related]
4. Emergency authorization of medical products: regulatory challenges from the 2009 H1N1 influenza pandemic in Japan.
Urushihara H; Matsui S; Kawakami K
Biosecur Bioterror; 2012 Dec; 10(4):372-82. PubMed ID: 23210832
[TBL] [Abstract][Full Text] [Related]
5. Emergency use authorization (EUA), conditional marketing authorization (CMA), and the precautionary principle at the time of COVID-19 pandemic.
Roncati L; Roncati M
J Public Health Policy; 2021 Sep; 42(3):518-521. PubMed ID: 34316006
[No Abstract] [Full Text] [Related]
6. Why emergency COVID-vaccine approvals pose a dilemma for scientists.
Cyranoski D
Nature; 2020 Dec; 588(7836):18-19. PubMed ID: 33230275
[No Abstract] [Full Text] [Related]
7. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
8. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.
Oliver SE; Gargano JW; Marin M; Wallace M; Curran KG; Chamberland M; McClung N; Campos-Outcalt D; Morgan RL; Mbaeyi S; Romero JR; Talbot HK; Lee GM; Bell BP; Dooling K
MMWR Morb Mortal Wkly Rep; 2021 Jan; 69(5152):1653-1656. PubMed ID: 33382675
[TBL] [Abstract][Full Text] [Related]
9. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
10. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
[TBL] [Abstract][Full Text] [Related]
11. The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021.
Mbaeyi S; Oliver SE; Collins JP; Godfrey M; Goswami ND; Hadler SC; Jones J; Moline H; Moulia D; Reddy S; Schmit K; Wallace M; Chamberland M; Campos-Outcalt D; Morgan RL; Bell BP; Brooks O; Kotton C; Talbot HK; Lee G; Daley MF; Dooling K
MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1545-1552. PubMed ID: 34735422
[TBL] [Abstract][Full Text] [Related]
12. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.
Singh JA; Upshur REG
Lancet Infect Dis; 2021 Apr; 21(4):e103-e109. PubMed ID: 33306980
[TBL] [Abstract][Full Text] [Related]
13. BNT162b2 mRNA COVID-19 Vaccine: First Approval.
Lamb YN
Drugs; 2021 Mar; 81(4):495-501. PubMed ID: 33683637
[TBL] [Abstract][Full Text] [Related]
14. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy.
Parums DV
Med Sci Monit; 2021 Sep; 27():e934625. PubMed ID: 34483336
[TBL] [Abstract][Full Text] [Related]
15. Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.
Thomson K; Nachlis H
JAMA; 2020 Oct; 324(13):1282-1283. PubMed ID: 32870235
[No Abstract] [Full Text] [Related]
16. Biodefense and emergency use authorization: different originations, purposes, and evolutionary paths of institutions in the United States and South Korea.
Kim H
Global Health; 2022 Dec; 18(1):100. PubMed ID: 36471373
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccines: rapid development, implications, challenges and future prospects.
Kashte S; Gulbake A; El-Amin Iii SF; Gupta A
Hum Cell; 2021 May; 34(3):711-733. PubMed ID: 33677814
[TBL] [Abstract][Full Text] [Related]
18. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.
MacNeil JR; Su JR; Broder KR; Guh AY; Gargano JW; Wallace M; Hadler SC; Scobie HM; Blain AE; Moulia D; Daley MF; McNally VV; Romero JR; Talbot HK; Lee GM; Bell BP; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(17):651-656. PubMed ID: 33914723
[TBL] [Abstract][Full Text] [Related]
19. A review of clinical efficacy data supporting emergency use authorization for COVID-19 therapeutics and lessons for future pandemics.
Yoo SH; Kim L; Lu M; Nagoshi K; Namchuk MN
Clin Transl Sci; 2022 Oct; 15(10):2279-2292. PubMed ID: 35929015
[TBL] [Abstract][Full Text] [Related]
20. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
Shay DK; Gee J; Su JR; Myers TR; Marquez P; Liu R; Zhang B; Licata C; Clark TA; Shimabukuro TT
MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):680-684. PubMed ID: 33956784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
